Silybin attenuates LPS-induced lung injury in mice by inhibiting NF-κB signaling and NLRP3 activation

Zhang,Bo; Wang,Bing; Cao,Shuhua; Wang,Yongqiang; Wu,Di

doi:10.3892/ijmm.2017.2935

Silybin attenuates LPS-induced lung injury in mice by inhibiting NF-κB signaling and NLRP3 activation

Authors:
- Bo Zhang
- Bing Wang
- Shuhua Cao
- Yongqiang Wang
- Di Wu
View Affiliations

Affiliations: Intensive Care Unit, Tianjin Huanhu Hospital, Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Hexi, Tianjin 300060, P.R. China, Intensive Care Unit, Tianjin First Center Hospital, Tianjin Ιnstitute of Εmergency Μedicine, Nankai, Tianjin 300192, P.R. China
Published online on: March 27, 2017 https://doi.org/10.3892/ijmm.2017.2935
Pages: 1111-1118
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Silybin is one of the main flavonoids produced by milk thistle, which has been used in the treatment of liver diseases. In this study, we examined the protective effects and possible mechanisms of action of silybin in lipopolysaccharide (LPS)‑induced lung injury and inflammation. Pre-treatment of mice with silybin significantly inhibited LPS-induced airway inflammatory cell recruitment, including macrophages, T cells and neutrophils. The production of cytokines, such as interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in bronchoalveolar fluid and serum was also decreased following treatment with silybin. Elevated cytokine mRNA levels induced by LPS in lung tissue were all suppressed by silybin and lung histological alterations were also improved. In addition, experiments using cells indicated that silybin significantly decreased the mRNA levels and secretion of IL-1β and TNF-α in THP-1 cells. Moreover, the mechanisms responsible for these effects were attributed to the inhibitory effect of silybin on nuclear factor-κB (NF-κB) signaling and NLR family pyrin domain containing 3 (NLRP3) inflammasome activation. The data form our study thus support the utility of silybin as a potential medicine for the treatment of acute lung injury‑associated inflammation and pathological changes. Silybin exerts protective effects against lung injury by regulating NF-κB signaling and the NLRP3 inflammasome activation.

View Figures

View References

1	Global Burden of Disease Study 2013 Collaborators: Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 386:743–800. 2015. View Article : Google Scholar
2	Han S and Mallampalli RK: The acute respiratory distress syndrome: From mechanism to translation. J Immunol. 194:855–860. 2015. View Article : Google Scholar : PubMed/NCBI
3	Ware LB and Matthay MA: The acute respiratory distress syndrome. N Engl J Med. 342:1334–1349. 2000. View Article : Google Scholar : PubMed/NCBI
4	Sadowitz B, Roy S, Gatto LA, Habashi N and Nieman G: Lung injury induced by sepsis: lessons learned from large animal models and future directions for treatment. Expert Rev Anti Infect Ther. 9:1169–1178. 2011. View Article : Google Scholar : PubMed/NCBI
5	Johnson ER and Matthay MA: Acute lung injury: Epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv. 23:243–252. 2010. View Article : Google Scholar : PubMed/NCBI
6	Sweeney RM, Griffiths M and McAuley D: Treatment of acute lung injury: current and emerging pharmacological therapies. Semin Respir Crit Care Med. 34:487–498. 2013. View Article : Google Scholar : PubMed/NCBI
7	Gekara NO, Dietrich N, Lyszkiewicz M, Lienenklaus S and Weiss S: Signals triggered by a bacterial pore-forming toxin contribute to toll-like receptor redundancy in gram-positive bacterial recognition. J Infect Dis. 199:124–133. 2009. View Article : Google Scholar
8	Jin LY, Li CF, Zhu GF, Wu CT, Wang J and Yan SF: Effect of siRNA against NF-kappaB on sepsisinduced acute lung injury in a mouse model. Mol Med Rep. 10:631–637. 2014.PubMed/NCBI
9	Zhu T, Wang DX, Zhang W, Liao X, Guan X, Bo H, Sun J, Huang N, He J, Zhang Y, et al: Andrographolide protects against LPS-induced acute lung injury by inactivation of NF-kappaB. PLoS One. 8:e564072013. View Article : Google Scholar
10	Xiao M, Zhu T, Zhang W, Wang T, Shen YC, Wan QF and Wen FQ: Emodin ameliorates LPS-induced acute lung injury, involving the inactivation of NF-kappaB in mice. Int J Mol Sci. 15:19355–19368. 2014. View Article : Google Scholar : PubMed/NCBI
11	Chen X, Yang X, Liu T, Guan M, Feng X, Dong W, Chu X, Liu J, Tian X, Ci X, et al: Kaempferol regulates MAPKs and NF-kappaB signaling pathways to attenuate LPS-induced acute lung injury in mice. Int Immunopharmacol. 14:209–216. 2012. View Article : Google Scholar : PubMed/NCBI
12	Rahman A and Fazal F: Blocking NF-kappaB: An inflammatory issue. Proc Am Thorac Soc. 8:497–503. 2011. View Article : Google Scholar : PubMed/NCBI
13	Elliott EI and Sutterwala FS: Initiation and perpetuation of NLRP3 inflammasome activation and assembly. Immunol Rev. 265:35–52. 2015. View Article : Google Scholar : PubMed/NCBI
14	Besnard AG, Guillou N, Tschopp J, Erard F, Couillin I, Iwakura Y, Quesniaux V, Ryffel B and Togbe D: NLRP3 inflammasome is required in murine asthma in the absence of aluminum adjuvant. Allergy. 66:1047–1057. 2011. View Article : Google Scholar : PubMed/NCBI
15	Sohn SH, Lee JM, Park S, Yoo H, Kang JW, Shin D, Jung KH, Lee YS, Cho J and Bae H: The inflammasome accelerates radiation-induced lung inflammation and fibrosis in mice. Environ Toxicol Pharmacol. 39:917–926. 2015. View Article : Google Scholar : PubMed/NCBI
16	Birrell MA and Eltom S: The role of the NLRP3 inflammasome in the pathogenesis of airway disease. Pharmacol Ther. 130:364–370. 2011. View Article : Google Scholar : PubMed/NCBI
17	Jia R, Cao L, Du J, Xu P, Jeney G and Yin G: The protective effect of silymarin on the carbon tetrachloride (CCl4)-induced liver injury in common carp (Cyprinus carpio). In Vitro Cell Dev Biol Anim. 49:155–161. 2013. View Article : Google Scholar : PubMed/NCBI
18	Sozmen M, Devrim AK, Tunca R, Bayezit M, Dag S and Essiz D: Protective effects of silymarin on fumonisin B1 induced hepatotoxicity in mice. J Vet Sci. 15:51–60. 2014. View Article : Google Scholar :
19	Schumann J, Prockl J, Kiemer AK, Vollmar AM, Bang R and Tiegs G: Silibinin protects mice from T cell-dependent liver injury. J Hepatol. 39:333–340. 2003. View Article : Google Scholar : PubMed/NCBI
20	Tzeng JI, Chen MF, Chung HH and Cheng JT: Silymarin decreases connective tissue growth factor to improve liver fibrosis in rats treated with carbon tetrachloride. Phytother Res. 27:1023–1028. 2013. View Article : Google Scholar
21	Khan AQ, Khan R, Tahir M, Rehman MU, Lateef A, Ali F, Hamiza OO, Hasan SK and Sultana S: Silibinin inhibits tumor promotional triggers and tumorigenesis against chemically induced two-stage skin carcinogenesis in Swiss albino mice: Possible role of oxidative stress and inflammation. Nutr Cancer. 66:249–258. 2014. View Article : Google Scholar
22	Kim BR, Seo HS, Ku JM, Kim G-J, Jeon CY, Park JH, Jang BH, Park SJ, Shin YC and Ko SG: Silibinin inhibits the production of pro-inflammatory cytokines through inhibition of NF-kappaB signaling pathway in HMC-1 human mast cells. Inflamm Res. 62:941–950. 2013. View Article : Google Scholar : PubMed/NCBI
23	Choi YH, Jin GY, Guo HS, Piao HM, Li L, Li GZ, Lin ZH and Yan GH: Silibinin attenuates allergic airway inflammation in mice. Biochem Biophys Res Commun. 427:450–455. 2012. View Article : Google Scholar : PubMed/NCBI
24	Kuo FH and Jan TR: Silibinin attenuates antigen-specific IgE production through the modulation of Th1/Th2 balance in ovalbumin-sensitized BALB/c mice. Phytomedicine. 16:271–276. 2009. View Article : Google Scholar
25	Schroder K and Tschopp J: The Inflammasomes. Cell. 140:821–832. 2010. View Article : Google Scholar : PubMed/NCBI
26	Sutterwala FS, Ogura Y, Szczepanik M, Lara-Tejero M, Lichtenberger GS, Grant EP, Bertin J, Coyle AJ, Galán JE, Askenase PW, et al: Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity. 24:317–327. 2006. View Article : Google Scholar : PubMed/NCBI
27	Sorbara MT and Girardin SE: Mitochondrial ROS fuel the inflammasome. Cell Res. 21:558–560. 2011. View Article : Google Scholar : PubMed/NCBI
28	Jangra A, Kasbe P, Pandey SN, Dwivedi S, Gurjar SS, Kwatra M, Mishra M, Venu AK, Sulakhiya K, Gogoi R, et al: Hesperidin and silibinin ameliorate aluminum-induced neurotoxicity: modulation of antioxidants and inflammatory cytokines level in mice hippocampus. Biol Trace Elem Res. 168:462–471. 2015. View Article : Google Scholar : PubMed/NCBI
29	Yan WJ, Tan YC, Xu JC, Tang XP, Zhang C, Zhang PB and Ren ZQ: Protective effects of silibinin and its possible mechanism of action in mice exposed to chronic unpredictable mild stress. Biomol Ther (Seoul). 23:245–250. 2015. View Article : Google Scholar
30	Duan S, Guan X, Lin R, Liu X, Yan Y, Lin R, Zhang T, Chen X, Huang J, Sun X, et al: Silibinin inhibits acetylcholinesterase activity and amyloid beta peptide aggregation: A dual-target drug for the treatment of Alzheimer's disease. Neurobiol Aging. 36:1792–1807. 2015. View Article : Google Scholar : PubMed/NCBI
31	Raghu R, Jesudas B, Bhavani G, Ezhilarasan D and Karthikeyan S: Silibinin mitigates zidovudine-induced hepatocellular degenerative changes, oxidative stress and hyperlipidaemia in rats. Hum Exp Toxicol. 34:1031–1042. 2015. View Article : Google Scholar : PubMed/NCBI
32	Braun DL, Rauch A, Aouri M, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Müllhaupt B, Metzner KJ, Decosterd L, et al: A lead-in with silibinin prior to triple-therapy translates into favorable treatment outcomes in difficult-to-treat HIV/hepatitis C coinfected patients. PLoS One. 10:e01330282015. View Article : Google Scholar : PubMed/NCBI
33	Cheung CWY, Gibbons N, Johnson DW and Nicol DL: Silibinin - A promising new treatment for cancer. Anticancer Agents Med Chem. 10:186–195. 2010. View Article : Google Scholar
34	Momeny M, Malehmir M, Zakidizaji M, Ghasemi R, Ghadimi H, Shokrgozar MA, Emami AH, Nafissi S, Ghavamzadeh A and Ghaffari SH: Silibinin inhibits invasive properties of human glioblastoma U87MG cells through suppression of cathepsin B and nuclear factor kappa B-mediated induction of matrix metalloproteinase 9. Anticancer Drugs. 21:252–260. 2010. View Article : Google Scholar : PubMed/NCBI
35	Li L, Zeng J, Gao Y and He DL: Targeting silibinin in the antiproliferative pathway. Expert Opin Investig Drugs. 19:243–255. 2010. View Article : Google Scholar : PubMed/NCBI
36	Hakansson HF, Smailagic A, Brunmark C, Miller-Larsson A and Lal H: Altered lung function relates to inflammation in an acute LPS mouse model. Pulm Pharmacol Ther. 25:399–406. 2012. View Article : Google Scholar : PubMed/NCBI
37	Mouratis MA, Magkrioti C, Oikonomou N, Katsifa A, Prestwich GD, Kaffe E and Aidinis V: Autotaxin and endotoxin-induced acute lung injury. PLoS One. 10:e01336192015. View Article : Google Scholar : PubMed/NCBI
38	No authors listed. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med. 342:1301–1308. 2000. View Article : Google Scholar
39	McKenna S and Wright CJ: Inhibiting IkappaBbeta-NFkappaB signaling attenuates the expression of select pro-inflammatory genes. J Cell Sci. 128:2143–2155. 2015. View Article : Google Scholar : PubMed/NCBI
40	Lee IT and Yang CM: Inflammatory signalings involved in airway and pulmonary diseases. Mediators Inflamm. 2013:7912312013. View Article : Google Scholar : PubMed/NCBI
41	Alvira CM: Nuclear factor-kappa-B signaling in lung development and disease: One pathway, numerous functions. Birth Defects Res A Clin Mol Teratol. 100:202–216. 2014. View Article : Google Scholar : PubMed/NCBI
42	Petrilli V, Papin S and Tschopp J: The inflammasome. Curr Biol. 15:R5812005. View Article : Google Scholar : PubMed/NCBI
43	Wen H, Ting JP and O'Neill LA: A role for the NLRP3 inflammasome in metabolic diseases - did Warburg miss inflammation? Nat Immunol. 13:352–357. 2012. View Article : Google Scholar : PubMed/NCBI
44	Shaw PJ, McDermott MF and Kanneganti TD: Inflammasomes and autoimmunity. Trends Mol Med. 17:57–64. 2011. View Article : Google Scholar :
45	Martinon F: Signaling by ROS drives inflammasome activation. Eur J Immunol. 40:616–619. 2010. View Article : Google Scholar : PubMed/NCBI